{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-138813","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2025-06-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.091452+00:00","generated_at":"2026-05-19T13:20:29.362099+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cogent Biosciences secures up to $400M non-dilutive debt facility; $50M drawn at closing","bullets":["$400M credit facility from SLR; first tranche of $50M funded on June 11, 2025.","Interest rate: 4.75% + greater of 1-month SOFR or 4.15%; matures June 1, 2030.","Future tranches tied to milestones: $25M after positive SUMMIT data, $75M after positive PEAK data.","$50M additional upon $85M net product revenue on trailing 6 months by June 30, 2027; $200M mutual.","Proceeds for working capital; monthly interest-only until June 1, 2028, with possible deferral to 2029."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-138813","json":"https://secwatch.observer/filing/0001193125-25-138813.json","markdown":"https://secwatch.observer/filing/0001193125-25-138813.md","text":"https://secwatch.observer/filing/0001193125-25-138813.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000119312525138813/0001193125-25-138813-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000119312525138813/d21181d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T13:20:29.362099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"390d5e362c9fd6c3bfef8b75a6fe96730ffe7203","claim":"Cogent Biosciences, Inc. incurred term loan of $50.0 million with SLR Investment Corp. at 4.75% plus the greater of (i) one-month term SOFR, and (ii) 4.15% per annum maturing June 1, 2030.","evidence_excerpt":"Security Agreement provides for a non-dilutive term loan facility (the “Credit Facility”) of up to an aggregate principal amount of $400.0 million, of which a first tranche of $50.0 million was fully funded on the Closing Date, with future tranches at the Company’s election subject to achievement of milestones consisting of (a) a second tranche of $25.0 million","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1622229/000119312525138813/0001193125-25-138813-index.htm","confidence":0.99,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$50.0 million"},{"label":"Counterparty","value":"SLR Investment Corp."},{"label":"Rate","value":"4.75% plus the greater of (i) one-month term SOFR, and (ii) 4.15% per annum"},{"label":"Maturity","value":"June 1, 2030"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}